Efficacy Of Retreatment Research Articles

Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection

Background. Hepatitis C is a leading cause of mortality among HIV-infected individuals. Therefore, eradication of HCV in this population is a priority. There are scarce data regarding retreatment efficacy of HIV/ HCV coinfected patients. The aim of our study was to evaluate efficacy, predictors of response, and long term clinical benefits of sustained virological response (SVR) after hepatitis C retreatment in a population of HIV/HCV coinfected patients.Material and methods. We evaluated efficacy, safety, and clinical benefits of peginterferon(alfa-2a or alfa-2b) and ribavirin in a restrospective, observational, multicentric study, including 47 HIV/HCV coinfected patients, non-responders to previous treatment with conventional interferon alfa-2a and ribavirin. The primary endpoint of efficacy was SVR, defined as undetectable viral load 24 weeks after end of treatment. Death, liver disease progression, CD4 counts, and AIDS defining illness were the endpoints to access clinical benefits of treatment response.Results. In our analysis, 31.9% patients reached SVR. Genotypes 2/3 had a significant better SVR (66.7%) compared to genotypes 1/4 (33.3%) (p = 0.022). During follow-up, deaths (6.89%) and hepatic decompensation (28.6%) occurred only in the nonresponder group, while there were no cases of death or hepatic decompensation among the responder group(p = 0.037).Conclusion. Nearly one third of patients (mainly those with genotypes 2/3) reached SVR after hepatitis C retreatment in this group of HIV/HCV coinfected patients. SVR was protective against hepatic decompensation and death in a two-year follow-up period. Retreatment may be an effective and safe way to eradicate HCV until new anti-HCV drugs become available to this group of patients.

Outcomes in patients (pts) with colorectal cancer (CRC) treated with oxaliplatin-based chemotherapy (OC) following prior oxaliplatin exposure.

500 Background: Pts frequently treated with OC in the adjuvant, perioperative, or first-line setting for CRC may be retreated with oxaliplatin at the time of relapse or progression; the efficacy of retreatment is not known. Methods: Under an IRB-approved protocol, the pharmacy records identified 1,166 pts who received OC for CRC at our institution from 1/1/2004-12/30/2009. Pts were categorized as having previously received OC initially for the indication of adjuvant (group A, n=29), unresectable metastatic disease (group B, n=75), or perioperative therapy for metastasectomy (group C, n =22). Results: Four RECIST responses (14%) were seen in group A (2 of these pts received cetuximab in combination), four responses in group B (5%), and no responses in group C. Retreatment with OC following initial oxaliplatin exposure was associated with a low radiographic and biochemical response rate and a short time to progression or withdrawal of OC (Table). Retreatment duration was limited by cumulative neurotoxicity and allergic reactions (data not presented). Significant activity was observed more frequently when a novel biologic agent was added to the pt's treatment. Conclusions: Retreatment with OC demonstrated minimal clinical efficacy and is limited by cumulative neurotoxicity and hypersensitivity reactions. [Table: see text]

Are Tyrosine Kinase Inhibitors Still Active in Patients With Metastatic Renal Cell Carcinoma Previously Treated With a Tyrosine Kinase Inhibitor and Everolimus? Experience of 36 Patients Treated in France in the RECORD-1 Trial

BackgroundBecause the response to treatment is limited, patients with metastatic renal cell carcinoma (mRCC) typically receive multiple treatments. Guidelines recommend everolimus for patients previously treated with tyrosine kinase inhibitors (TKI) sunitinib or sorafenib. This study evaluated the efficacy of TKI re-treatment in patients with disease progression after a TKI-everolimus sequence. Patients and MethodsData were reviewed for patients enrolled in RECORD-1 (Renal Cell Cancer Treatment With Oral RAD001 Given Daily) at French sites. Response, progression-free survival (PFS), and overall survival were evaluated in patients treated with a TKI-everolimus-TKI sequence. ResultsThirty-six patients received a TKI after everolimus: sunitinib in 17 patients, sorafenib in 15, and dovitinib (TKI258) in 4. The response rate with TKI re-treatment was 8%, and the disease-control rate (response plus stable disease) was 75%. The median PFS with each component of the TKI-everolimus-TKI sequence was 10.7 months (95% CI, 1.8-28.5 months), 8.9 months (95% CI, 1.7-34.6 months), and 8.2 months (95% CI, 5.2-11.9 months), respectively. The median overall survival from the start of everolimus was 29.1 months (95% CI 21.1 to not reached months), which suggests a benefit in using TKI in this setting. ConclusionsAdministration of a TKI-everolimus-TKI sequence may be associated with clinical benefit and should be prospectively investigated.

A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma

Multiple myeloma (MM) typically follows a relapsing course with many patients requiring multiple therapies. This single-arm phase 2 study prospectively evaluated the efficacy and safety of bortezomib retreatment in MM patients who had relapsed after achieving at least a partial response (≥ PR) to prior bortezomib-based therapy. Patients aged ≥ 18 years, with measurable, secretory MM, who relapsed ≥ 6 months after prior bortezomib treatment were eligible. Patients received up to eight cycles of bortezomib (± dexamethasone). The primary endpoint was best confirmed response at retreatment; secondary endpoints included duration of response (DOR), time to progression (TTP), and safety. Adverse events (AEs) were graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. A total of 130 patients (median of two prior lines of therapy) were enrolled and received retreatment. At retreatment, 28% and 72% of patients received bortezomib and bortezomib-dexamethasone, respectively. Overall response rate was 40%. In patients who achieved ≥ PR, median DOR and TTP were 6.5 and 8.4 months, respectively. Thrombocytopenia was the most common grade ≥ 3 AE (35%). Forty percent of patients experienced neuropathy events, which improved and resolved in a median of 1.5 and 8.9 months, respectively. In conclusion, bortezomib retreatment was effective and tolerable in relapsed MM patients, with no evidence of cumulative toxicities.

A multicenter survey of re‐treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan

This study aimed to clarify the factors associated the efficacy of re-treatment with pegylated interferon (PEG IFN) plus ribavirin combination therapy for patients with chronic hepatitis C who had failed to respond to previous treatment. One hundred and forty-three patients who had previously shown relapse (n = 79), non-response (n = 34) or intolerance (n = 30) to PEG IFN plus ribavirin were re-treated with PEG IFN plus ribavirin. Twenty-five patients with intolerance to previous treatment completed re-treatment and the sustained virological response (SVR) rates were 55% and 80% for hepatitis C virus (HCV) genotype 1 and 2, respectively. On re-treatment of the 113 patients who completed the previous treatment, the SVR rates were 48% and 63% for genotype 1 and 2, respectively. Relapse after previous treatment and a low baseline HCV RNA level on re-treatment were associated with SVR in genotype 1 (P < 0.001). Patients with the interleukin-28B major genotype responded significantly better and earlier to re-treatment, but the difference in the SVR rate did not reach a significant level between the major and minor genotypes (P = 0.09). Extended treatment of 72 weeks raised the SVR rate among the patients who attained complete early virological response but not rapid virological response with re-treatment (72 weeks, 73%, 16/22, vs 48 weeks, 38%, 5/13, P < 0.05). Relapse after previous treatment and a low baseline HCV RNA level have predictive values for a favorable response of PEG IFN plus ribavirin re-treatment for HCV genotype 1 patients. Re-treatment for 72 weeks may lead to clinical improvement for genotype 1 patients with complete early virological response and without rapid virological response on re-treatment.

Efficacy of the retreatment of hepatitis C virus infections after liver transplantation: Role of an aggressive approach

A sustained virological response (SVR) is achieved by 30% of naive liver transplantation (LT) recipients treated with pegylated interferon (PEG-IFN) and ribavirin (RBV). Almost no data are available about retreatment. The aim of this study was to assess the efficacy, tolerability, and SVR predictors of retreatment. Data were collected from 4 centers on the retreatment of prior nonresponders to standard therapy or PEG-IFN (with or without RBV) and relapsers. Seventy-nine of 301 treatment-experienced LT patients (26%), who had a median age of 59 years (range = 35-77 years) and were mostly male (72%) and infected with genotype 1 (87%), were retreated with PEG-IFN and RBV at a median of 6.9 years after LT. During the first course of therapy, 35% were treated with interferon, 49% received tacrolimus, 52% received steroids, and 49.5% were relapsers. Retreatment was started at a median of 1.9 years (range = 45 days to 8.2 years) after the end of the first course. The proportion of patients with cirrhosis increased from 10% to 37% (P < 0.001). In addition, in retreated patients, full initial RBV doses (P = 0.03), growth factors [erythropoietin (P < 0.001) and granulocyte colony-stimulating factor (P = 0.048)], and transfusions (P = 0.03) were used more frequently, and the treatment duration was longer (P = 0.03). An end-of-treatment response was achieved in 61%, whereas SVR, which was associated with improved survival, occurred in 28 (35%). The variables predicting SVR were age (P = 0.04), disease severity [fibrosis (50% with F0-F2 versus 26% with F3-4), P = 0.03; bilirubin, P = 0.006; platelet count, P = 0.03], adherence, and viral kinetics. None of the patients without an early virological response achieved SVR. There was a trend of prior relapsers achieving higher SVR rates than prior nonresponders. In conclusion, SVR, which was achieved by approximately one-third of the retreated patients, can be predicted with the same variables used for naive LT recipients (age, disease severity, adherence, and viral kinetics) and is associated with enhanced survival.

Retreatment with Peginterferon α-2a + Ribavirin in Patients Who Failed Previous Peginterferon α-2b + Ribavirin Combination Therapy

Background/Aims: Peginterferon (PEG-IFN) + ribavirin (RBV) combination therapy is the current standard of care for chronic hepatitis C. However, more than half of the patients cannot achieve sustained viral response (SVR). In Japan, the clinical benefit of retreatment with PEG-IFN + RBV combination retreatment is still unknown. Methods: We collected clinical data in 106 chronic hepatitis C patients who failed to achieve SVR with PEG-IFNα-2b + RBV combination therapy and were retreated with PEG-IFNα-2a + RBV. This retrospective study examined the efficacy of retreatment with PEG-IFNα-2a + RBV by evaluating the time to eradication of hepatitis C virus RNA, early virological response (EVR), and SVR. We compared the results of the previous therapy and retreatment in terms of efficacy and analyzed the factors influencing SVR. Results: The SVR rates in the non-responders and relapsers were 11 and 53%, respectively. EVR and prolonged treatment duration were associated with SVR. We also found that a prior response to PEG-IFN + RBV therapy was more important than the Interleukin-28B genotype for predicting the response to retreatment. Conclusions: Retreatment with PEG-IFNα-2a + RBV should be considered for relapsers and partial responders. Our results suggest that prolonged administration is also favorable for EVR cases to attain a higher SVR.

Meta-Analysis of the Efficacy and Safety of Bortezomib Retreatment in Patients with Multiple Myeloma (MM)

AbstractAbstract 1863 Introduction:Bortezomib is approved for the treatment of MM, and bortezomib-based therapies are a cornerstone of care for both first-line and relapsed and/or refractory MM. As bortezomib is administered for a finite course, as opposed to treatment being continued to disease progression, patients may remain sensitive to bortezomib-based therapy at relapse. A number of prospective and retrospective studies in patients with relapsed and/or refractory MM have demonstrated the efficacy of subsequent retreatment with bortezomib-containing regimens. We report a systematic literature review and meta-analysis to assess the efficacy and safety of bortezomib-based retreatment in relapsed and/or refractory MM. Methods:Using PubMed and major hematology/oncology conference proceedings, a systematic literature review was performed to identify studies from January 2005 to May 2012 of bortezomib-based therapy in patients with relapsed and/or refractory MM. All studies of bortezomib-based retreatment in MM patients with prior exposure to bortezomib were systematically selected. Treatments were classified as bortezomib ± dexamethasone (dex) or bortezomib-based combinations. The proportion of bortezomib-refractory patients was identified for each study where available. Additional prognostic factors, including number of prior therapies, proportion of patients with prior autologous stem cell transplant (ASCT), and time since last bortezomib, were extracted and used in weighted stratified analyses of time to progression (TTP), progression-free survival (PFS), and overall survival (OS). Random-effect pooled estimates (taking into account heterogeneity across studies) were calculated for overall response rate (ORR; partial response or better) and rates of common adverse events (AEs). A meta-regression was conducted to explore the interactive effects of prognostic factors on ORR. Results:Twenty-three studies (N=1051 patients) were identified. Bortezomib was administered IV in all studies. Retreatment comprised bortezomib ± dex in 5 studies and combination therapy in 18. Bortezomib-refractory patients were included in 11 studies (10–100% of patients), 6 studies included only relapsed patients, and data were not available for 6 studies. Across studies in which data were available, the pooled, weighted average ORR was 39% (95% CI: 31–47) and the pooled, weighted average median TTP, PFS, and OS were 7.5, 5.8, and 16.6 months, respectively. Data from stratified univariate analyses are shown in the table. Outcomes appeared generally consistent across groups while patients with fewer prior therapies (≤4) and relapsed (but not refractory) patients achieved higher ORRs of 43% (95% CI: 31–55) and 57% (95% CI: 45–69), respectively. Random-effects meta-regression analysis controlling for number of prior therapies and % prior ASCT confirmed that, compared to refractory patients, relapsed patients were associated with a higher ORR by 28–41 percentage points. In studies of bortezomib ± dex in patients with a median age >65 years and with a lower % of patients receiving prior ASCT (≤30%), retreatment remained active (pooled average ORR of 51%, median TTP and OS of 8.4 and 19.2 months). The most common grade 3/4 AEs included thrombocytopenia (35%), neutropenia (15%), anemia (14%), pneumonia (10%), and peripheral neuropathy (3%). Conclusions:Based on these findings, retreatment with bortezomib alone or in combination is efficacious and well tolerated in relapsed patients, with an ORR of 57% and median TTP and OS of 8.5 and 19.7 months. In an era of new and emerging treatment options for relapsed and/or refractory MM, these data indicate bortezomib retreatment remains a highly effective therapeutic option in previously treated patients.VariableORR, %TTP, monthsOS, monthsAll patients397.516.6Bortezomib-refractory:0% (relapsed only)578.519.7<50%28––≥50%195.920.4100% (refractory only)23–11.2Unknown496.0–Prior therapies:≤4438.213.3>4297.120.0Unknown455.6–Prior ASCT:<50%568.819.7≥50%196.415.9Unknown455.813.0Time since last bortezomib:<9 months499.519.7≥9 months437.3–Unknown305.915.4Therapy:Bortezomib ± dex517.919.2Combination367.116.1 Disclosures:Knopf:Millennium Pharmaceuticals, Inc.: Consultancy. Duh:Millennium Pharmaceuticals, Inc.: Research Funding. Lafeuille:Millennium Pharmaceuticals, Inc.: Research Funding. Gravel:Millennium Pharmaceuticals, Inc.: Research Funding. Lefebvre:Millennium Pharmaceuticals, Inc.: Research Funding. Niculescu:Millennium Pharmaceuticals, Inc.: Employment. Ba-Mancini:Millennium Pharmaceuticals, Inc.: Employment. Ma:Millennium Pharmaceuticals, Inc.: Employment. Shi:Millennium Pharmaceuticals, Inc.: Employment. Comenzo:Millennium Pharmaceuticals, Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding.

Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma

This open-label phase III trial, a companion to an earlier placebo-controlled trial, evaluated safety and efficacy of denileukin diftitox (DD) in patients with cutaneous T-cell lymphoma (CTCL) who relapsed after responding to DD primary treatment in the earlier trial. Twenty relapsed patients (stages IA–III) received DD 18 μg/kg/day intravenously on days 1–5 of a 21-day cycle, for ≤8 cycles. Efficacy was assessed monthly during the first year then every 3 months. The overall response rate was 40%, mostly partial responses. Nine patients (all baseline stages ≤ IIA) experienced progression. Intent-to-treat median progression-free survival was 205 days, and median duration of response was 274 days. The most common adverse events were nausea, upper respiratory tract infections, fatigue and rigors. Three patients withdrew because of toxicity. This study showed that DD may provide clinically meaningful benefit in patients with CTCL who relapsed after initial response to DD.

396 - Efficacy of Trastuzumab Containing Retreatment after Progression on Lapatinib Therapy in Japanese Patients with HER2-Positive Metastatic Breast Cancer

ABSTRACT Background Lapatinib has been approved for HER2 positive metastatic breast cancer patients with refractory to trastuzumab (T) therapy in Japan. Currently, it has been proposed that lapatinib can resensitize trastuzumab–mediated antibody-dependent cellular cytotoxicity (ADCC). Recent clinical data suggest the efficacy of T containing retreatment after progression on lapatinib therapy in patients with HER2-positive metastatic breast cancer. Here, we present a retrospective review of data from 25 patients who received T containing retreatment after progression on lapatinib therapy. Methods We reviewed the data of 50 patients with HER2-positive metastatic breast cancer who received lapatinib therapy in our institution from August 2004 through March 2012. Of these, 25 patients received T containing retreatment after progression on lapatinib therapy. We retrospectively assessed the clinical benefit of this treatment regimen in these patients. Results Luminal-HER2 and HER2-enriched subtypes were identified in 13 (52%) and 12 (48%) of these cases, respectively. The median duration of lapatinib therapy was 5.9 months (range, 1.8-20.2 months). The median number of preceding regimens was 3 (range, 2-8) in metastatic setting. Seven patients (31.8%) responded to T containing retreatment; all 7 patients achieved PR and none achieved CR. There were no significant differences in subtype, number of preceding regimens and brain metastases; however, responders achieved higher clinical response from lapatinib therapy than non-responders (response rate of 84% versus 13%, respectively). The median time to progression of T containing retreatment was 3.0 months (95% CI, 2.4-3.5 months). Among seven responders to T containing retreatment, one patient responded to refractory T containing regimen. All patients tolerated T containing retreatment with no occurrence of Grade 3/4 toxicities. Conclusion T containing retreatment could be a favorable treatment regimen which can achieve clinical response in patients with HER2-positive metastatic breast cancer who experienced progression on prior trastuzumab and following lapatinib therapy. Disclosure All authors have declared no conflicts of interest.

Retreatment with purine analogs in patients with chronic lymphocytic leukemia

We evaluated the efficacy and toxicity of retreatment with purine analogs (PA) in 62 patients with relapsed chronic lymphocytic leukemia. Median OS and PFS after retreatment were 60 and 26 months, respectively. By multivariate analysis, minimal residual disease status, ZAP-70 expression and age had independent predictive power in terms of OS. Toxicity was mainly neutropenia (21%) and infections (39%). Second malignancies were observed in 10 (16%) patients. Our results outline that retreatment with PA is remarkably effective in patients with relapsed CLL, but with a significant toxicity.

Efficacy of Re-treatment With TMC435 as Combination Therapy in Hepatitis C Virus–Infected Patients Following TMC435 Monotherapy

In the TMC435-C101 study, 6 patients infected with hepatitis C virus genotype 1 were treated with the protease inhibitor TMC435 (200 mg once daily) as monotherapy for 5 days. Approximately 1.5 years later, 5 of these patients were re-treated with TMC435 (200 mg once daily) plus pegylated interferon alfa-2a and ribavirin (PegIFNα-2a and RBV) for 4 weeks, followed by PegIFNα-2a and RBV until week 48 (in the Optimal Protease inhibitor Enhancement of Response to therApy [OPERA-1] study). TMC435-resistant variants, which emerged in all 5 patients during the TMC435-C101 study, were no longer detected at the beginning of the OPERA-1 study based on virus population sequencing. During the OPERA-1 study, 3 patients had a sustained virologic response; deep sequencing indicated low-level persistence of resistant variants in the remaining 2 patients, which might have affected their response to re-treatment.

Changes in sequences of core region, interferon sensitivity‐determining region and interferon and ribavirin resistance‐determining region of hepatitis C virus genotype 1 during interferon‐alpha and ribavirin therapy, and efficacy of retreatment

Some regions associated with sensitivity to interferon-α and ribavirin have been identified in the hepatitis C virus (HCV) genome, including amino acid 70 in the core region (core a.a. 70), a.a. 2209-2248 (interferon sensitivity-determining region, ISDR) and a.a. 2334-2379 (interferon and ribavirin resistance-determining region, IRRDR). We examined changes in the sequences of these regions in 25 patients with chronic HCV genotype 1 infection who had not had sustained virological response (SVR) to interferon-α and ribavirin for 24-48 weeks and subsequently received retreatment for 48-72 weeks. At baseline, the core a.a. 70 was mutant (resistant) type in seven patients. At the start of retreatment, the core a.a. 70 had changed from sensitive to resistant type in 2 patients, and SVR was not achieved by retreatment. The ISDR variations were resistant type (0-1 mutations) in 17 patients at baseline. After 2 weeks of treatment, amino acid change was found in two patients; in one, the substitutions returned to baseline status after treatment, and in the other, the substitution persisted. At the start of retreatment, ISDR sequences had changed from resistant to sensitive type in two patients and SVR was achieved and from sensitive to resistant type in three patients and SVR was not achieved. The IRRDR variations were resistant type (<6 mutations) in 19 patients at baseline and at the start of retreatment. Sequences of the core region and ISDR sometimes change during anti-HCV therapy, potentially affecting the outcomes of retreatment.

PTU-102 Re-treatment with infliximab after a prolonged drug holiday in patients with Crohn's disease

IntroductionInfliximab (IFX) is a chimeric monoclonal antibody effective for inducing and maintaining remission in Crohn's disease. The safety and efficacy of retreatment with IFX after a short “drug holiday” was...

Reply

Reply

Long‐term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open‐label extension study

REVEAL was a 52-week study of adalimumab for moderate to severe psoriasis. At Week 33, adalimumab-treated patients with sustained responses (PASI ≥75 at Weeks 16 and 33) were re-randomized to receive adalimumab or placebo. Subsequently, they could receive adalimumab in an open-label extension (OLE) study. To compare long-term efficacy and safety of adalimumab 40 mg every other week (eow), given as continuous treatment or with one period of interruption followed by retreatment. Patients who were re-randomized to adalimumab or placebo at REVEAL Week 33 and received ≥ 1 dose of OLE adalimumab were analysed as the continuous and retreatment groups, respectively, for >2 years of OLE treatment with adalimumab 40 mg eow. LOCF was used for missing efficacy data. At OLE Weeks 0, 12 and 24, PASI 75 response rates were 84%, 84%, 86% with continuous treatment (N = 233) vs. 45%, 71%, 79% with retreatment (N = 227). Thereafter, efficacies were slightly greater for continuous treatment but similar between groups, with PASI 75 response rates at OLE Week 108 of 75% vs. 73% respectively. Retreatment was most effective for patients with ≥ PASI 50 responses when retreatment was initiated. Adverse event rates for retreatment were equal to or lower than those for continuous treatment. In psoriasis patients with sustained PASI 75 responses to adalimumab, long-term efficacy of retreatment after a ≤ 19-week interruption was similar to efficacy achieved with > 3 years continuous treatment. Adalimumab retreatment provided the best results when initiated before responses had declined below PASI 50.

Efficacy of different doses of rituximab for the treatment of RA: data From the CERERRA collaboration

Background/objectivesThe approved dose of RTX in RA is 1000 mg x2, but some data have suggested similar clinical efficacy with 500 mg x2. The purpose of this analysis was to...

Second-line treatment for renal cell cancer

Second-line treatment for renal cell cancer

Impact of ribavirin dose on retreatment of chronic hepatitis C patients

To study the efficacy and factors associated with a sustained virological response (SVR) in chronic hepatitis C (CHC) relapsing patients. Out of 1228 CHC patients treated with pegylated interferon (PEG-IFN) and ribavirin (RBV), 165 (13%) had a relapse. Among these, 62 patients were retreated with PEG-IFN-α2a or -α2b and RBV. Clinical, biological, virological and histological data were collected. Initial doses and treatment modifications were recorded. The efficacy of retreatment and predictive factors for SVR were analyzed. An SVR was achieved in 42% of patients. SVR was higher in young (< 50 years) (61%) than old patients (27%) (P = 0.007), and in genotype 2 or 3 (57%) than in genotype 1 or 4 (28%) patients (P = 0.023). Prolonging therapy for at least 24 wk more than the previous course was associated with higher SVR rates (53% vs 28%, P = 0.04). Also, a better SVR rate was observed with RBV dose/body weight > 15.2 mg/kg per day (70% vs 35%, P = 0.04). In logistic regression, predictors of a response were age (P = 0.018), genotype (P = 0.048) and initial RBV dose/body weight (P = 0.022). None of the patients without a complete early virological response achieved an SVR (negative predictive value = 100%). Retreatment with PEG-IFN/RBV is eff-ective in genotype 2 or 3 relapsers, especially in young patients. A high dose of RBV seems to be important for the retreatment response.

Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy

Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy